作者
Rutger T. Theijse,Thomas F. Stoop,T. Hendriks,J Annelie Suurmeijer,F. Jasmijn Smits,Bert A. Bonsing,Daan J. Lips,Eric R. Manusama,Erwin van der Harst,Gijs A. Patijn,Jan H. Wijsman,Mark Meerdink,Marcel den Dulk,Ronald M. van Dam,Martijn W J Stommel,Cornelis J. H. M. van Laarhoven,Roeland F. de Wilde,Sebastiaan Festen,Werner A. Draaisma,K. Bosscha,Casper H.J. van Eijck,Olivier R. Busch,I. Quintus Molenaar,Bas Groot Koerkamp,Hjalmar C. van Santvoort,Marc G. Besselink
摘要
Objective: To assess nationwide surgical outcome after pancreatoduodenectomy (PD) in patients at very high risk for postoperative pancreatic fistula (POPF), categorized as ISGPS-D. Summary Background Data: Morbidity and mortality after ISGPS-D PD is perceived so high that a recent randomized trial advocated prophylactic total pancreatectomy (TP) as alternative aiming to lower this risk. However, current outcomes of ISGPS-D PD remain unknown as large nationwide series are lacking. Methods: Nationwide retrospective analysis including consecutive patients undergoing ISGPS-D PD (i.e., soft texture and pancreatic duct ≤3 mm), using the mandatory Dutch Pancreatic Cancer Audit (2014-2021). Primary outcome was in-hospital mortality and secondary outcomes included major morbidity (i.e., Clavien-Dindo grade ≥IIIa) and POPF (ISGPS grade B/C). The use of prophylactic TP to avoid POPF during the study period was assessed. Results: Overall, 1402 patients were included. In-hospital mortality was 4.1% ( n =57), which decreased to 3.7% ( n =20/536) in the last 2 years. Major morbidity occurred in 642 patients (45.9%) and POPF in 410 (30.0%), which corresponded with failure to rescue in 8.9% ( n =57/642). Patients with POPF had increased rates of major morbidity (88.0% vs. 28.3%; P <0.001) and mortality (6.3% vs. 3.5%; P =0.016), compared to patients without POPF. Among 190 patients undergoing TP, prophylactic TP to prevent POPF was performed in 4 (2.1%). Conclusion: This nationwide series found a 4.1% in-hospital mortality after ISGPS-D PD with 45.9% major morbidity, leaving little room for improvement through prophylactic TP. Nevertheless, given the outcomes in 30% of patients who develop POPF, future randomized trials should aim to prevent and mitigate POPF in this high-risk category.